Global pharmaceutical company Lupin Limited has taken a significant step in enhancing its specialty ophthalmology business by acquiring VISUfarma B.V., a company specializing in eye health products. The acquisition, finalized on September 29, 2025, involves Lupin’s wholly owned subsidiary, Nanomi B.V., and was made in collaboration with GHO Capital Partners LLP, VISUfarma’s previous owner.
The integration of VISUfarma is a strategic move for Lupin, aligning with its objective to expand its presence in the European market and enhance its global specialty franchise. With an established portfolio of over 60 branded ophthalmology products, VISUfarma brings a robust commercial infrastructure that promises to accelerate Lupin’s growth in this sector. This market expansion is particularly timely, as the global ophthalmology market is experiencing rapid growth due to an aging population and rising incidences of diabetes-related eye complications.
Vinita Gupta, CEO of Lupin, expressed enthusiasm about the acquisition, stating, “We are delighted to welcome VISUfarma into the Lupin family. This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve.” She noted that the move not only enhances Lupin’s European footprint but also solidifies its position in the specialty ophthalmology space.
The established operations of VISUfarma across key European countries—including Italy, the UK, Spain, Germany, and France—will facilitate Lupin’s entry into new markets. This integration is expected to provide numerous growth opportunities, particularly in areas such as dry eye treatment, glaucoma, eyelid hygiene, and retinal health.
Lupin plans to finance the acquisition using existing cash reserves, and it is anticipated to contribute positively to both the company’s growth and margin profiles. The transaction is projected to close by the end of 2025, contingent upon the satisfaction of certain closing conditions.
GHO Capital has played a pivotal role in transforming VISUfarma from a domestic Italian entity into a significant player in the European ophthalmic market. According to Andrea Ponti, Managing Partner at GHO Capital, their collaboration with the VISUfarma management team has established a strong operational presence in key markets, positioning the company well for future growth.
VISUfarma’s CEO for Italy, Paolo Cioccetti, commented on the acquisition, stating, “Combining with Lupin represents an exciting new chapter for VISUfarma. We will build towards a global ophthalmology franchise with a commitment to advancing eye care and improving patient outcomes.”
This acquisition marks a noteworthy moment for Lupin as it continues to expand its portfolio and enhance its capabilities in the specialty pharmaceutical sector. With a firm commitment to innovation and patient care, Lupin is poised to make significant strides in the ophthalmology market.
Founded in 2016, VISUfarma has established itself as a leader in ophthalmology pharmaceuticals, generating €48 million in revenue in 2024 across multiple European markets. The company has been backed by GHO Capital since its inception, which has provided strategic guidance and support throughout its development.
With this acquisition, Lupin not only strengthens its position in ophthalmology but also reinforces its broader mission of improving patient health outcomes worldwide. The company operates with over 15 state-of-the-art manufacturing sites and 7 research centers globally, employing more than 24,000 professionals dedicated to advancing healthcare solutions.
For further details about Lupin and its offerings, visit their official website or follow them on social media platforms.
